Dr. Myra Wick, Dr. Andrea Wahner Hendrickson and Teri Woodhull talk about the importance of genetics and genetic testing in ovarian cancer and the implications for treatment, with special attention to PARP inhibitors. They discuss different options for genetic testing, indications for PARP inhibitors and how to make a decision regarding PARP inhibitor treatment or maintenance. Teri Woodhull discusses the experience of being on an inhibitor including risks and side effects.
This webinar is a collaboration between Mayo Clinic, the Foundation for Women's Cancer and the Minnesota Ovarian Cancer Alliance.
These webinars were hosted by the Foundation for Women's Cancer. You can find the archived recordings of this webinar and many more on their website here: